Figure 4.

Prediction of favorable or unfavorable efficacy in patients with or without grade ≥2 skin rash within each observation period. The proportions of patients with favorable efficacy in the severe rash (grade ≥2) group (positive predictive value, dashed line) and of patients with unfavorable efficacy in the mild rash (grade <2) group (negative predictive value, solid line) within each observation period (2, 4, 6, and 8 weeks and the entire treatment course) in terms of (A) response, (B) Progression-free survival (PFS) and (C) overall survival (OS). Favorable efficacy is defined as complete or partial response, PFS >6 months and OS >12 months. Unfavorable efficacy is defined as stable or progressive disease, PFS <6 months and OS <12 months. All, entire treatment course.